Abstract
Recently, [8] has proposed that heterogeneity of infectiousness (and susceptibility) across individuals in infectious diseases, plays a major role in affecting the Herd Immunity Thresh-old (HIT). Such heterogeneity has been observed in COVID-19 and is recognized as overdis-persion (or “super-spreading”). The model of [8] suggests that super-spreaders contribute significantly to the effective reproduction factor, R, and that they are likely to get infected and immune early in the process. Consequently, under R0 ≈ 3 (attributed to COVID-19), the Herd Immunity Threshold (HIT) is as low as 5%, in contrast to 67% according to the traditional models [1, 2, 4, 10].
This work follows up on [8] and proposes that heterogeneity of infectiousness (susceptibility) has two “faces” whose mix affects dramatically the HIT: (1) Personal-Trait-, and (2) Event-Based-Infectiousness (Susceptibility). The former is a personal trait of specific individuals (super-spreaders) and is nullified once those individuals are immune (as in [8]). The latter is event-based (e.g cultural super-spreading events) and remains effective throughout the process, even after the super-spreaders immune. We extend [8]’s model to account for these two factors, analyze it and conclude that the HIT is very sensitive to the mix between (1) and (2), and under R0 ≈ 3 it can vary between 5% and 67%. Preliminary data from COVID-19 suggests that herd immunity is not reached at 5%.
We address operational aspects and analyze the effects of lockdown strategies on the spread of a disease. We find that herd immunity (and HIT) is very sensitive to the lock-down type. While some lockdowns affect positively the disease blocking and increase herd immunity, others have adverse effects and reduce the herd immunity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part by Len Blavatnik and the Blavatnik Family foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
irrelevant
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Online data sources and cited papers/books can be found at the list of references.
